U.S. Scientists demonstrate efficacy of VM202

A team of the U.S. scientists have discovered that VM202, a newly constructed plasmid human hepatocyte growth factor, improved myocardial perfusion, viability, and LV function in pigs, opening new possibilities for treatment of coronary artery disease (CAD).

The University of California team, led by Dr. Maythem Saeed, said that in chronic infarction, VM202 increased maximum signal intensity ...